|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, April 23, 2016 ) The Type 2 Diabetes Mellitus Therapeutics Market Report shows that this chronic hyperglycemia is associated with long-term damage, dysfunction and failure of multiple organs including the eyes, kidneys, nerves, heart and blood vessels. The vast majority of diabetes mellitus patients can be classified as having either Type 1 Diabetes Mellitus (T1DM) or Type 2 Diabetes Mellitus (T2DM). Approximately 85-95% of all diabetics have T2DM.
T2DM treatment has been revolutionized in the past decade, especially with the increased use of new therapies. The marketed products landscape comprises a wide range of treatment options, including biguanide (metformin), sulfonylureas, thiazolidinediones, GLP-1 receptor agonist, DPP-4 inhibitor, SGLT-2 inhibitor, and insulin therapies.
Other Key Points in Report:
The current T2DM in the Asia-Pacific (APAC) market contains novel products, including Jardiance-a SGLT-2 inhibitor; Victoza-a GLP-1 receptor agonist; and Galvus-a DPP-4 inhibitor.
-What are the competitive advantages of the existing novel drugs?
With over 500 active pipeline molecules, most of the late-stage investigational drug candidates are being evaluated, featuring improved dosing regimens and administration routes, in comparison to currently marketed products and combination therapies.
-Which classes of novel drugs are most prominent within the pipeline?
-Is there strong potential for the pipeline to address unmet needs within the T2DM market?
Analysis of clinical trials, since 2006, identified that the failure rates of T2DM molecules were highest in Phase II, at 54%, with the overall attrition rate for T2DM at 82.6%.
-How do failure rates vary by product stage of development, molecule type, and mechanism of action?
-How do other factors, such as average trial duration and trial size influence the costs and risks associated with product development?
Inquire before Buying Report@ http://www.reportsweb.com/inquiry&RW0001170041/buying
Table of Content: An Overview
2 Introduction 9
2.1 Disease Overview 9
2.2 Classification 9
2.3 Symptoms 10
2.4 Etiology 10
2.5 Pathophysiology 11
2.6 Epidemiology 13
2.7 Prognosis 13
2.8 Co-morbidities and Complications 14
2.9 Diagnosis 15
2.10 Assessing Treatment Effectiveness 17
2.11 Treatment 17
2.11.1 Non-insulin T2DM Therapies 19
2.11.2 Insulin T2DM Therapies 22
2.12 Treatment Segments 24
2.12.1 Non-insulin therapies 24
2.12.2 Insulin Therapies 39
3 Marketed Products 43
3.1 Overview 43
3.2 Biguanides 44
3.2.1 Metformin 44
3.3 Sulfonylureas 45
3.4 Thiazolidinediones 47
3.4.1 Pioglitazone 47
Ask for Discount on Report @ http://www.reportsweb.com/inquiry&RW0001170041/discount
3.6 DPP-4 Inhibitors 55
3.6.1 Januvia/Glactiv (sitagliptin) 55
3.6.2 Galvus (vildagliptin) 56
3.6.3 Onglyza (saxagliptin) 57
3.6.4 Trazenta (linagliptin) 58
3.6.5 Zafatek (trelagliptin succinate) 59
3.6.6 Marizev (omarigliptin) 60
3.7 SGLT-2 Inhibitors 61
3.7.1 Forxiga (dapagliflozin) 61
3.7.2 Invokana (canagliflozin) 62
3.7.3 Jardiance (empagliflozin) 63
3.8 Insulin Therapies 63
3.8.1 Lantus (insulin glargine) 63
3.8.2 Levemir (insulin detemir) 64
3.8.3 Tresiba (insulin degludec) 65
3.8.4 Toujeo/ Lantus XR (insulin glargine) 66
3.9 Marketed Products Heat Maps 67
4 Pipeline 70
4.1 Overview 70
4.2 Pipeline Distribution by Stage of Development, Molecule Type and Program Type 71
4.3 Pipeline Distribution by Molecular Target 72
4.4 Clinical Trial Landscape 79
4.4.1 Clinical Trial Failure Rates 79
4.4.2 Clinical Trial Duration 84
4.4.3 Clinical Trial Size 87
4.4.4 Clinical Trial Metrics Analysis 90
4.5 Promising Pipeline Molecules 92
4.5.1 NN-9535 (subcutaneous semaglutide) and OG-217SC (oral semaglutide)-Novo Nordisk 92
4.5.2 ITCA 650-Intarcia Therapeutics 94
4.5.3 Ertugliflozin-Pfizer 96
4.6 Pipeline Products Heat Map 98
Purchase Complete Report @ http://www.reportsweb.com/buy&RW0001170041/buy/4995
About ReportsWeb:
ReportsWeb.com is a one stop shop of market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost effective research reports and solutions from various publishers. We provide best in class customer service and our customer support team is always available to help you on your research queries.
Contact Us:
Call: +1-646-491-9876
Email: sales@reportsweb.com
ReportsWeb.com
Priya Sisodia
+1-646-491-9876
sales@reportsweb.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
